106 related articles for article (PubMed ID: 19440016)
21. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
22. Cardiopulmonary bypass influences the plasma levels of calcitonin gene-related peptides in dogs: effects of hemofiltration and hemodilution.
Isaka M; Imamura M; Sakuma I; Makino Y; Shiiya N; Yasuda K
Res Vet Sci; 2007 Feb; 82(1):110-4. PubMed ID: 16839577
[TBL] [Abstract][Full Text] [Related]
23. The promiscuous receptor.
Newsom-Davis TE; Kenny LM; Ngan S; King J; Waxman J
BJU Int; 2009 Nov; 104(9):1204-7. PubMed ID: 19426197
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level.
Nakagawa T; Kanai Y; Komiyama M; Fujimoto H; Kakizoe T
Cancer Sci; 2009 Oct; 100(10):1880-4. PubMed ID: 19659608
[TBL] [Abstract][Full Text] [Related]
25. Plasma changes of calcitonin gene-related peptide and substance P in patients with dialysis headache.
Alessandri M; Massanti L; Geppetti P; Bellucci G; Cipriani M; Fanciullacci M
Cephalalgia; 2006 Nov; 26(11):1287-93. PubMed ID: 17059435
[TBL] [Abstract][Full Text] [Related]
26. Measurement of CGRP in dried blood spots using a modified sandwich enzyme immunoassay.
Song EY; Vandunk C; Kuddo T; Nelson PG
J Neurosci Methods; 2006 Jul; 155(1):92-7. PubMed ID: 16466803
[TBL] [Abstract][Full Text] [Related]
27. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression.
Johnke RM; Edwards JM; Evans MJ; Nangami GN; Bakken NT; Kilburn JM; Lee TK; Allison RR; Karlsson UL; Arastu HH
In Vivo; 2009; 23(5):827-33. PubMed ID: 19779119
[TBL] [Abstract][Full Text] [Related]
28. Calcitonin gene-related peptide is a survival factor, inhibiting apoptosis in neonatal rat gubernaculum in vitro.
Chan JJ; Farmer PJ; Southwell BR; Sourial M; Hutson JM
J Pediatr Surg; 2009 Aug; 44(8):1497-501. PubMed ID: 19635294
[TBL] [Abstract][Full Text] [Related]
29. [Role of hormonal profile in adjusting therapy for prostate cancer].
Granov AM; Molchanov OE; Karelin MI
Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
[TBL] [Abstract][Full Text] [Related]
30. Calcitonin gene related peptide in familial dysautonomia.
Maayan C; Becker Y; Gesundheit B; Girgis SI
Neuropeptides; 2001; 35(3-4):189-95. PubMed ID: 11884210
[TBL] [Abstract][Full Text] [Related]
31. [Calcitonin gene-related peptide (CGRP)].
Ikeda Y; Takami H
Nihon Rinsho; 1999 Dec; 57 Suppl():121-3. PubMed ID: 10778080
[No Abstract] [Full Text] [Related]
32. Calcitonin gene-related peptide levels in saliva of patients with burning mouth syndrome.
Zidverc-Trajkovic J; Stanimirovic D; Obrenovic R; Tajti J; Vécsei L; Gardi J; Németh J; Mijajlovic M; Sternic N; Jankovic L
J Oral Pathol Med; 2009 Jan; 38(1):29-33. PubMed ID: 19192048
[TBL] [Abstract][Full Text] [Related]
33. [Calcitonin gene-related peptide (CGRP)].
Ikeda Y; Takami H
Nihon Rinsho; 2010 Jul; 68 Suppl 7():328-30. PubMed ID: 20963878
[No Abstract] [Full Text] [Related]
34. Neuronal calcitonin gene-related peptide promotes prostate tumor growth in the bone microenvironment.
Zhu W; Sheng D; Shao Y; Zhang Q; Peng Y
Peptides; 2021 Jan; 135():170423. PubMed ID: 33086087
[TBL] [Abstract][Full Text] [Related]
35. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin receptor-stimulating peptide: Its evolutionary and functional relationship with calcitonin/calcitonin gene-related peptide based on gene structure.
Katafuchi T; Yasue H; Osaki T; Minamino N
Peptides; 2009 Sep; 30(9):1753-62. PubMed ID: 19540291
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
38. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
39. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
Miller K
MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
[No Abstract] [Full Text] [Related]
40. Reduced serum selenoprotein P concentrations in German prostate cancer patients.
Meyer HA; Hollenbach B; Stephan C; Endermann T; Morgenthaler NG; Cammann H; Köhrle J; Jung K; Schomburg L
Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2386-90. PubMed ID: 19690186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
